An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
AlloVir Announces Departure of Chief Medical Officer Augustin Melian
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
AlloVir (Nasdaq: ALVR) announced the departure of Chief Medical Officer Dr. Augustin Melian at year-end 2023. Dr. Melian joined the company in March 2019 and significantly advanced the clinical development of its lead product, posoleucel. He will assist in transitioning to ensure continuity. Richard Riese, SVP of Clinical Research, will oversee ongoing clinical programs, including the Phase 3 studies for posoleucel. AlloVir focuses on innovative cell therapies targeting life-threatening viral diseases for patients with weakened immune systems.
Positive
Dr. Melian's leadership contributed to advancing posoleucel into Phase 3 clinical development.
Richard Riese will continue overseeing clinical programs, ensuring stability in leadership.
Negative
The departure of Dr. Melian may cause uncertainty in the company's strategic direction.
WALTHAM, Mass.--(BUSINESS WIRE)--
AlloVir (Nasdaq: ALVR) today announced that Augustin Melian, MD, Chief Medical Officer, has decided to leave the company at the end of this year. Although officially leaving the company, Dr. Melian has agreed to work with AlloVir in an advisory capacity to ensure a smooth transition.
Dr. Melian joined AlloVir in March 2019 and under his leadership, the company has advanced its lead product posoleucel into Phase 3 clinical development and shaped the clinical development programs for its investigational therapies targeting respiratory viruses.
“Over the last two and half years, Tino has been instrumental in expanding and advancing our pipeline of virus-specific T cells. I’m very grateful for his contributions, which have helped establish AlloVir as a leader in this field and position us well for our next stage of growth,” said Diana Brainard, MD, Chief Executive Officer, AlloVir.
Richard Riese, MD, PhD, Senior Vice President, Clinical Research, will continue to lead the company’s clinical development programs, including oversight of the Phase 3 studies for posoleucel.
About AlloVir AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information, visit www.allovir.com or follow us on Twitter or LinkedIn.
